timothy sykes logo

Stock News

InMed Pharmaceuticals: Recent Moves and Financial Insights

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 11/20/2025, 9:19 am ET 11/20/2025, 9:19 am ET | 5 min 5 min read
InMed Pharmaceuticals: Recent Moves and Financial Insights Thumbnail

InMed Pharmaceuticals Inc. stocks have been trading up by 11.41 percent due to promising news on cannabinoid R&D advancements.

Candlestick Chart

Live Update At 09:18:38 EST: On Thursday, November 20, 2025 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending up by 11.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview of Financial Reports

Over the last few days, the stock price of InMed Pharmaceuticals Inc. (INM) has seen some fluctuations according to recent trading data. On Nov 18, 2025, INM’s stock opened at $1.63 and closed at $1.46, reflecting investor sentiment perhaps tied to advancements in their clinical trials. Despite having a rollercoaster ride in the market, there is considerable interest surrounding their pipeline development, particularly after the pharmacokinetic studies.

The financial metrics provide an interesting narrative, especially given that InMed is still in the clinical stages. The company’s revenue for the latest quarter stands at approximately $4.9M, which, although a modest figure, shows that they are making headway. Key ratios indicate challenges; notably, the EBIT margin is at -163.8%, underscoring the capital-intensive nature of pharmaceutical R&D and the early stage of INM’s products. The price-to-book ratio at 0.4 signals potential undervaluation compared to the net asset value.

A deep dive into the financial reports indicates cash changes where the end cash position is $9.33M, showing a decrease from the previous quarter, primarily due to significant R&D expenses. With a current ratio of 7 and a quick ratio of 6.3, INM appears well-positioned in terms of liquidity, a crucial factor for companies in drug development phases, as high liquidity allows operations to continue amidst high expenses with limited revenue.

Detailed Analysis of Articles and Market Impact

In the world of trading, it’s crucial to understand that success isn’t solely determined by the amount of money you earn from trades. Risk management and capital preservation play significant roles. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” Traders need to focus on strategies that minimize losses and protect their capital, ensuring long-term profitability and sustainable growth in their trading journey.

The recent positive results from their pharmacokinetic studies bring hope for further development in the Alzheimer’s treatment space. Alzheimer’s, a significant unmet medical need, attracts investor interest towards biotech firms pursuing new treatment avenues. Successfully completing the studies for INM-901 isn’t just science on paper; it can lead to promising future clinical trials in humans if regulatory approvals are greenlit.

When dissected, InMed’s advancements in these studies might do more than uplift investor sentiment in the short term. It could set a precedent for new partnerships or funding opportunities, bolstering their financial standing for future research phases. The intricate dance between scientific milestone and market response underscores the biotech sector’s complex reality where science often spearheads valuation spikes or slumps.

Given the present stock patterns and how market chatter responds to clinical success, INM’s dance in the stock charts doesn’t merely bounce on news of successful trials but also the broader context of potential industry advancements and competitive landscapes. News of study completions can temporarily remove some clouds over the company, enticing speculative plays and strategic trading positions.

More Breaking News

Projections and Potential Market Movements

The stock performance, influenced by the news, charts InMed’s course amidst complexities of drug development. INM’s share price will primarily hinge on further developments regarding INM-901 and other pipeline candidates, coupled with the overall biotech climate, which is often sensitive to regulatory news and competitor actions.

To anticipate INM’s trajectory, one must look at the financial fundamentals juxtaposed with ongoing R&D developments. While fiscal figures tell of current standing, the sentiment from clinical success colors what may lie ahead, particularly if they can reduce burn rates through strategic partnerships or increased trader interests stemming from successful research outcomes. As INM forges ahead in its quest for breakthroughs, stakeholders will keenly weigh optimism against the realities of biotech trading risks.

In conclusion, although there remains inherent uncertainty, the advancement shared in the recent news highlights a path forward for InMed. As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” The critical juncture lies in how well they can convert research milestones into commercial and financial success—an art as much as a science in the pharmaceutical landscape. As we track INM, these findings convey both challenges and opportunities, underscoring the intricate interplay between development news and market perceptions, crucial for guiding trading ladders in the biotechnology maze.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”